TIDMPRTC
PureTech Health PLC
06 January 2023
6 January 2023
PureTech Health plc
PureTech Founded Entity Akili Announces Pivotal Trial of
EndeavorRx (R) in Adolescents with ADHD Shows Robust Improvements
in Attention and Broader Clinical Outcomes
Attention improvements were nearly three times as large as those
in the pivotal trial that served as the basis for EndeavorRx's FDA
authorization for children with ADHD ages 8-12
Study data will be used to file for EndeavorRx label expansion
with FDA in 2023
Akili has stopped recruitment in separate adult ADHD trial to
allow for earlier data analysis
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company noted today
that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) ("Akili"), a
leading digital medicine company, announced topline results of the
STARS-ADHD-Adolescents label expansion study evaluating the
efficacy and safety of EndeavorRx(R) (AKL-T01) in adolescents ages
13-17 with attention-deficit/hyperactivity disorder (ADHD).
The pivotal study achieved its predefined primary efficacy
outcome, showing statistically significant improvement in
attentional functioning after four weeks of treatment. Consistent
improvements were also seen in a range of secondary measures of
ADHD-related inattention symptoms and functioning. EndeavorRx
treatment was generally well-tolerated, with no serious
device-related adverse events reported.
Akili plans to present full data from the STARS-ADHD-Adolescents
study at a future medical meeting, and the company will file for
EndeavorRx label expansion with FDA in 2023. As part of Akili's
label expansion strategy for EndeavorRx, in addition to the study
in adolescents, the company has been conducting a separate pivotal
trial of EndeavorRx in adults with ADHD. As was previously noted
during the company's last earnings call, recruiting for that adult
study has been slower than projected. Based on this strong clinical
data in adolescents and the desire to maximize capital efficiency,
Akili has stopped recruitment of the adult study with 224 patients
enrolled in order to analyze the trial data ahead of schedule.
The full text of the announcement from Akili is as follows:
Pivotal Trial of EndeavorRx (R) in Adolescents with ADHD Shows
Robust Improvements in Attention and Broader Clinical Outcomes
Attention improvements were nearly three times as large as those
in the pivotal trial that served as the basis for EndeavorRx's FDA
authorization for children with ADHD ages 8-12
Study data will be used to file for EndeavorRx label expansion
with FDA in 2023
Akili has stopped recruitment in separate adult ADHD trial to
allow for earlier data analysis
BOSTON - January 5, 2023 - - Akili, Inc. (Nasdaq: AKLI), a
leading digital medicine company, today announced topline results
of the STARS-ADHD-Adolescents label expansion study evaluating the
efficacy and safety of EndeavorRx (AKL-T01) in adolescents ages
13-17 with attention-deficit/hyperactivity disorder (ADHD). The
pivotal study achieved its predefined primary efficacy outcome,
showing statistically significant improvement in attentional
functioning after four weeks of treatment. Consistent improvements
were also seen in a range of secondary measures of ADHD-related
inattention symptoms and functioning. EndeavorRx treatment was
generally well-tolerated, with no serious device-related adverse
events reported.
"The results of this study extend the already substantial
evidence base to support the efficacy of EndeavorRx for improving
attentional functioning in patients with ADHD, and most importantly
show the ability of this safe treatment to help teenagers, who have
been significantly impacted by the current mental health crisis,"
said Scott Kollins, Ph.D., chief medical officer of Akili.
The multi-center open-label study enrolled 162 adolescents ages
13-17 with inattentive or combined-type ADHD. In the study,
EndeavorRx demonstrated a statistically significant improvement in
the Test of Variables of Attention (TOVA(R))-Attention Comparison
Score (ACS) of sustained and selective attention from baseline
after one month of treatment (p<0.0001), the study's predefined
primary efficacy outcome. The change from baseline on the TOVA ACS
was nearly three times as large as the changes seen in STARS-ADHD,
a large randomized controlled trial of children with ADHD ages 8-12
that served as the basis for EndeavorRx's U.S. Food and Drug
Administration (FDA) authorization in that age group. In the
STARS-ADHD-Adolescents study, nearly two-thirds (66%) of
adolescents met the prespecified definition of clinical response on
the TOVA-ACS and nearly a quarter (24.7%) moved into the
non-clinical, or normative, range. TOVA is a computerized test
cleared by FDA to assess attention deficits and evaluate the
effects of interventions in ADHD.
Adolescents using EndeavorRx also saw significant improvement in
ADHD symptoms, as measured by the Attention Deficit Hyperactive
Disorder Rating Scale-5 (ADHD-RS) inattention subscale and total
scale scores. ADHD-RS is a clinician-administered questionnaire
based on information collected from the child's caregiver.
Following treatment, participants in the study showed significant
improvement on both the inattention subscale and total score of the
ADHD-RS (p<0.0001 for both). A prespecified responder analysis
also showed that 27.1% of all participants in the study
demonstrated at least a 30% reduction in total scores on the
ADHD-RS, a finding similar to the STARS-ADHD trial in children with
ADHD (24%). Statistically significant improvements were also
observed for parent and child ratings of attention improvement, as
well as parent ratings of function across a number of domains,
including peer relationships, academic functioning, behavioral
functioning, homework functioning, and self-esteem. Overall, 4
(2.5%) participants experienced a treatment-emergent adverse device
event (3 decreased frustration tolerance, 1 headache; all mild or
moderate). There were no serious adverse device events.
Akili plans to present full data from the STARS-ADHD-Adolescents
study at a future medical meeting, and the company will file for
EndeavorRx label expansion with FDA in 2023. As part of Akili's
label expansion strategy for EndeavorRx, in addition to the study
in adolescents, the company has been conducting a separate pivotal
trial of EndeavorRx in adults with ADHD. As was previously noted
during the company's last earnings call, recruiting for that adult
study has been slower than projected. Based on this strong clinical
data in adolescents and the desire to maximize capital efficiency,
Akili has stopped recruitment of the adult study with 224 patients
enrolled in order to analyze the trial data ahead of schedule.
EndeavorRx Indication and Overview
EndeavorRx is the first-and-only FDA-authorized treatment
delivered through a video game experience. EndeavorRx is indicated
to improve attention function as measured by computer-based testing
in children ages 8 to 12 years old with primarily inattentive or
combined-type ADHD, who have a demonstrated attention issue.
Patients who engage with EndeavorRx demonstrate improvements in a
digitally assessed measure Test of Variables of Attention (TOVA(R))
of sustained and selective attention and may not display benefits
in typical behavioral symptoms, such as hyperactivity. EndeavorRx
should be considered for use as part of a therapeutic program that
may include clinician-directed therapy, medication, and/or
educational programs, which further address symptoms of the
disorder. EndeavorRx is available by prescription only. It is not
intended to be used as a stand-alone therapeutic and is not a
substitution for a child's medication. The most common side effect
observed in children in EndeavorRx's clinical trials was a feeling
of frustration, as the game can be quite challenging at times. No
serious adverse events were associated with its use. EndeavorRx is
recommended to be used for approximately 25 minutes a day, 5 days a
week, over initially at least 4 consecutive weeks, or as
recommended by your child's health care provider. To learn more
about EndeavorRx, please visit EndeavorRx.com .
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Akili's approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine - medicine that is validated through
clinical trials like a drug or medical device but experienced like
entertainment. Akili's platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili's belief that
effective medicine can also be fun and engaging, Akili's products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. These forward-looking statements generally are
identified by the words "believe, " "project," "expect,"
"anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
Forward-looking statements are predictions, projections, and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties.
These forward-looking statements include, without limitation,
statements in this press release related to: our expectations with
respect to timing of a regulatory submission to FDA for EndeavorRx
(AKL-T01) and our aim to expand the EndeavorRx label; our clinical
development plans, including the timing of enrollment for and
analysis of data from clinical trials as well as the release of
additional clinical data; and the likelihood that data from
clinical trials will be positive and support further clinical
development and regulatory approval of AKL-T01. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties, and important factors that may cause actual events
or results to differ materially from those expressed or implied by
any forward-looking statements contained in this press release,
including, without limitation, risks and uncertainties related to:
the risk that prior results, such as signals of efficacy or safety
observed from clinical trials of AKL-T01 will not continue or be
repeated in our ongoing or planned clinical trials of AKL-T01, will
be insufficient to support regulatory submissions or support or
maintain marketing approval in the United States or other
jurisdictions, or that long-term adverse safety findings may be
discovered; the risk that AKL-T01 will not be further developed or
commercialized successfully; the timing and results expected from
our and our partners' clinical trials and our reliance on third
parties for certain aspects of our business; our ability to
accurately estimate expenses, capital requirements, and needs for
additional financing; and other risks identified in our current
filings and any subsequent filings made with the Securities and
Exchange Commission (SEC). We caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof and should not be relied upon as representing the
company's views as of any subsequent date. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions, or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.
About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the
treatment paradigm for devastating diseases. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two (Plenity(R) and EndeavorRx(R)) that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that will soon be filed for FDA
approval, as of the most recent update by the Company. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to the pivotal
trial of Akili's EndeavorRx in adolescents with ADHD and
expectations related to the timing of the filing for EndeavorRx
label expansion with FDA, the pivotal trial of Akili's EndeavorRx
in adults, and PureTech's future prospects, development plans, and
strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2021 filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUPPGUPWPUA
(END) Dow Jones Newswires
January 06, 2023 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024